Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

N-004

Supelco

Naloxone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H21NO4
CAS Number:
465-65-6
Molecular Weight:
327.37
EC Number:
200-659-6
MDL number:
MFCD00242634
UNSPSC Code:
41116107
PubChem Substance ID:
329818392
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC=C

InChI

1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1

InChI key

UZHSEJADLWPNLE-GRGSLBFTSA-N

Gene Information

human ... OPRD1(4985) , OPRK1(4986) , OPRM1(4988)

Looking for similar products? Visit Product Comparison Guide

General description

Naloxone is an opiate drug used to counter the effects of opioid overdose. This certified solution standard is applicable for use in LC/MS or GC/MS applications such as clinical toxicology and forensic analysis. Naloxone is sold under the trade names Narcan®, Nalone, and Narcan®ti.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Narcan is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

IMPN-007-04

Naloxone N-oxide solution, 100 μg/mL in acetonitrile: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

N-063

Naloxone-D5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-924

Nalorphine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

N-115

Naloxone-D5 solution, 1.0 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-004S

Naloxone solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R Terry Furst
Journal of addictive diseases, 32(1), 53-67 (2013-03-14)
This study explores strategies that Suboxone misusers utilize while in drug treatment. Ethnographic interviews were conducted with 14 patients who had cycled in and out of Suboxone treatment. The objective of the study is to identify strategies implemented by patients
Jason Boland et al.
Clinical medicine (London, England), 13(2), 149-151 (2013-05-18)
Opioids can induce respiratory depression by invoking a centrally mediated decrease in involuntary respiratory rate, which in severe cases can cause a decrease in oxygen saturation. If respiratory depression is opioid induced, both low respiratory rate and low oxygen saturation
Anne M Neumann et al.
Journal of addictive diseases, 32(1), 68-78 (2013-03-14)
Patients with opioid addiction who receive prescription opioids for treatment of nonmalignant chronic pain present a therapeutic challenge. Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone. At the 6-month follow-up examination, 26 (48.1%)
Severe postoperative hyperthermic syndrome after addition of tilidine/naloxone to duloxetine therapy.
Marco Vinetti et al.
Clinical toxicology (Philadelphia, Pa.), 51(6), 516-517 (2013-06-19)
Robert Taylor et al.
Expert opinion on investigational drugs, 22(4), 517-525 (2013-03-15)
Opioid receptor antagonists are well known for their ability to attenuate or reverse the effects of opioid agonists. This property has made them useful in mitigating opioid side effects, overdose and abuse. Paradoxically, opioid antagonists have been reported to produce
View All Related Papers

Articles

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service